Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970580 · ClinicalTrials.gov registry record · Phase 1
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00970580 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 18 participants.
The verdict
NCT00970580, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Interventions
- DRUG BIIB022 With Paclitaxel and Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00970580
The ClinicalTrials.gov registry entry for NCT00970580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB022 With Paclitaxel and Carboplatin is the first listed.
NCT00970580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00970580 about?
NCT00970580 is a clinical study titled "A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer". The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
What is the current status of trial NCT00970580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-10. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00970580?
The interventions under investigation include: BIIB022 With Paclitaxel and Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00970580?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.